Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Oxford Racing Ahead With 8,000 Vaccinated In Phase III Trial

Plus: Eisai Joins RE-MAP Cap Study

Executive Summary

Partnering with AstraZeneca, the Oxford team has opened up a clear lead in the race to enrol thousands of patients for late-stage safety and efficacy trials – but cannot make guarantees of when results might be ready.

You may also be interested in...



Coronavirus Update: 'Positive News' Imminent From Oxford and AstraZeneca Vaccine

More news from across the sector, including Novartis's non-profit pledge on medicines and Zydus Cadila commencing Phase I vaccine trial.

UK Uses Local Outbreak Data To Target Coronavirus Vaccine Trials

The UK Vaccine Taskforce is helping to troubleshoot for COVID-19 candidates including in clinical trials and manufacturing scale-up.

Coronavirus Update: Moderna Hold Up, Sanofi and Regeneron's Kevzara Fails In Phase III

Delay to Moderna's Phase III plans adds to the biotech's rollercoaster ride, but its CEO insists it is still on track.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142510

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel